Celadon Pharmaceuticals PLC (GB:CEL) has released an update.
Celadon Pharmaceuticals Plc, a UK-based leader in cannabis-based medicines, has announced its first international commercial shipment to a major US customer. This marks a significant milestone, showcasing the company’s expansion capabilities, and follows a lucrative £26m European supply contract. The recent deals emphasize the global demand for Celadon’s high-quality medical cannabis products and their strong position in the international pharmaceutical market.
For further insights into GB:CEL stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
